Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 9/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514986 | 0.85 | KHK (0.44) | KHKHPGDALDH1A1HTTHSD17B10 | |
| SCHEMBL4522989 | 0.84 | KHK (0.60) | KHKCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL4507115 | 0.80 | KHK (0.63) | KHKCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL4505301 | 0.79 | KHK (0.54) | KHKCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL4512852 | 0.78 | KHK (0.55) | KHKCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL4511884 | 0.78 | KHK (0.54) | KHKCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL4596672 | 0.77 | KHK (0.54) | KHKCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL4522433 | 0.76 | KHK (0.53) | KHKCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL13865894 | 0.74 | KHK (0.62) | KHKCCNE1CDK2HPGDALDH1A1 | |
| SCHEMBL13865930 | 0.74 | KHK (0.61) | KHKCCNE1CDK2HPGDTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | KHK 3420/4885CCNE1 4430/4885CDK2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.